<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01428388</url>
  </required_header>
  <id_info>
    <org_study_id>CRAVE1</org_study_id>
    <nct_id>NCT01428388</nct_id>
  </id_info>
  <brief_title>Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion</brief_title>
  <acronym>CRAVE</acronym>
  <official_title>Comparison of Anti-vascular Endothelial Growth Factors Agents in the Treatment of Macular Edema Following Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barnes Retina Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Retina Associates of Florida, P.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Illinois Retina Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kresge Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Long Island Vitreoretinal Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mid Atlantic Retina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Retina Associates, Kansas City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barnes Retina Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in
      treating macular edema resulting from retinal vein occlusion (RVO). In the eye, the two most
      widely used anti-VEGF agents are ranibizumab and bevacizumab. Only ranibizumab has been
      FDA-approved for the treatment of macular edema from RVO, however bevacizumab has been used
      off-label by many ophthalmologists with good success. Furthermore, the cost of bevacizumab is
      less than one-tenth the cost of ranibizumab. Here the investigators conduct a six month
      randomized, prospective interventional trial comparing the effectiveness of ranibizumab with
      bevacizumab in the treatment of macular edema from RVO. Primary outcome measures are change
      in central retinal thickness. Secondary measures are change in visual acuity from baseline
      and change in angiographic properties of macular lesions from baseline after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in central retinal thickness</measure>
    <time_frame>six months compared to baseline</time_frame>
    <description>central thickness is measured using optical coherence tomography (OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in best-corrected Snellen visual acuity</measure>
    <time_frame>six months compared to baseline</time_frame>
    <description>best-corrected Snellen visual acuity (BCVA) is the best visual acuity measured using a standard Snellen eye chart at 20 feet between (1) uncorrected vision, (2) vision with current eyeglasses or (3) pinholed visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in fluorescein angiogram</measure>
    <time_frame>six months compared to baseline</time_frame>
    <description>fluorescein angiograms will measure area of peripheral nonperfusion. This will be interpreted by a designated physician at each testing center.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of bevacizumab</intervention_name>
    <description>1.25 mg per dose, delivered monthly by intravitreal injection for six months</description>
    <arm_group_label>Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal injection of ranibizumab (0.5 mg per dose)</intervention_name>
    <description>0.5 mg per dose, delivered monthly by intravitreal injection for six months</description>
    <arm_group_label>Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Visual acuity of 20/40 - 20/320 in the study eye (regardless of relative APD)

          -  Central foveal thickness (CFT) of &gt; 250 microns as assessed by OCT (see below)

          -  Diagnosis of retinal vein occlusion in the past 9 months

          -  Age over 50 years

        Exclusion Criteria:

          -  History of previous intraocular surgery in the study eye, including pars plana
             vitrectomy (but not including uncomplicated cataract surgery), within 60 days of the
             screening visit

          -  Inability to make study visits

          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) â‰¥ 25
             mmHg) despite treatment with two or more topical pharmacological anti-glaucomatous
             medication)

          -  Pregnancy or lactation

          -  Evidence of any diabetic retinopathy on exam or history of diabetic macular edema
             within 12 weeks of study onset

          -  Any intravitreal injections within 12 weeks of study onset

          -  Prior retinal vein occlusion

          -  History of pan-retinal photocoagulation within 3 months of study onset or anticipated
             within 4 months after study onset

          -  History of cerebrovascular event or myocardial infarction within 3 months of study
             onset
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>September 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2011</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barnes Retina Institute</investigator_affiliation>
    <investigator_full_name>Rhonda Weeks</investigator_full_name>
    <investigator_title>Gaurav Shah, MD</investigator_title>
  </responsible_party>
  <keyword>macular edema</keyword>
  <keyword>vein occlusion</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

